Status:
TERMINATED
Tofacitinib Registry of Patients With Ulcerative Colitis in Germany
Lead Sponsor:
Ced Service GmbH
Collaborating Sponsors:
Pfizer
Conditions:
Colitis, Ulcerative
Biologics
Eligibility:
All Genders
18-80 years
Brief Summary
This registry on Tofacitinib and biologics (anti-integrin/anti-TNF) in the treatment of ulcerative colitis (UC) patients in Germany will extend the prospective documentation of safety issues and effic...
Detailed Description
This is an Investigator-initiated non-randomized, non-interventional observational prospective long- term research (IIR) as part of the normal treatment of UC patients for the safety and efficacy of T...
Eligibility Criteria
Inclusion
- Patients with moderate to severe Ulcerative Colitis aged 18-80 years at enrollment
- Written informed consent is given
Exclusion
- Malignant disease in history (except for non-melanoma skin cancer)
- Any contraindication according to the SmPC of the respective medication
Key Trial Info
Start Date :
August 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 15 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04032756
Start Date
August 1 2019
End Date
November 15 2020
Last Update
October 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gastroenterologische Gemeinschaftspraxis Minden
Minden, Lower Saxony, Germany, 32423